Astellas snaps up mitochondria-focused biotech, beefs up drug discovery in budget deal
Astellas has shown it can go big when it sees something it wants for the sprawling R&D organization it’s building, wagering $3 billion on gene therapy upstart Audentes and $665 million on Xyphos Biosciences’ Parker-backed CAR-T platform. But it can also go small. In its latest deal, the Japanese pharma is subsuming Nanna Therapeutics into its European unit for less than $15 million (£12 million).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.